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Abstract
Background: To compare definitive radiochemotherapy with weekly administration of 30–40 mg/m2 of cisplatin to
100 mg/m2 of cisplatin on days 1, 22 and 43 for outcomes and toxicity in patients with squamous cell carcinoma of
the head-and-neck.
Methods: Seventy-five patients receiving radiochemotherapy with weekly cisplatin (30–40 mg/m2) were compared
to 58 patients receiving radiochemotherapy with 100 mg/m2 cisplatin on days 1, 22 and 43. Radiochemotherapy
regimen plus seven characteristics (age, gender, performance score, tumor site, T-/N-category, histologic grading)
were evaluated for locoregional control (LRC), metastases-free survival (MFS) and overall survival (OS).
Radiochemotherapy groups were compared for toxicity.
Results: On multivariate analysis, improved LRC was associated with cisplatin 100 mg/m2 (hazard ratio [HR] 1.57; p = 0.
008) and female gender (HR 4.37; p = 0.003). Radiochemotherapy regimen was not significantly associated with MFS on
univariate analysis (p = 0.66). On multivariate analysis, better MFS was associated with ECOG performance score 0–1 (HR
5.63; p < 0.001) and histological grade 1–2 (HR 1.81; p = 0.002). On multivariate analysis, improved OS was associated
with cisplatin 100 mg/m2 (HR 1.33; p = 0.023), ECOG performance score 0–1 (HR 2.15; p = 0.029) and female gender (HR
1.98; p = 0.026). Cisplatin 100 mg/m2 was associated with higher rates of grade ≥3 hematotoxicity (p = 0.004), grade ≥2
renal failure (p = 0.004) and pneumonia/sepsis (p = 0.033).
Conclusions: Radiochemotherapy with 100 mg/m2 of cisplatin every 3 weeks resulted in better LRC and OS than
weekly doses of 30–40 mg/m2. Given the limitations of a retrospective study, 100 mg/m2 of cisplatin appears
preferable. Since this regimen was associated with considerable acute toxicity, patients require close monitoring.
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Background
Many patients with locally advanced squamous cell carcin-
oma of the head-and-neck (SCCHN) are not candidates
for surgical resection and receive definitive radiotherapy.
After randomized trials had demonstrated that radioche-
motherapy was superior to radiotherapy alone for defini-
tive treatment of SCCHN, radiochemotherapy became the
standard treatment for these patients [1–3]. According to
a large meta-analysis, concurrent administration of ra-
diochemotherapy resulted in significantly better out-
comes than sequential approaches [4]. This meta-analysis
included patients who received radiochemotherapy with
cisplatin alone or various poly-chemotherapy regimens,
including combined cisplatin-based regimens, but did not
show significantly superiority of a particular regimen.
Thus, the most appropriate chemotherapy given concur-
rently with radiation therapy for locally advanced SCCHN
requires further clarification.
In two randomized trials comparing radiochemotherapy
and radiotherapy alone after surgery for SCCHN in patients
with risk factors, radiochemotherapy with 100 mg/m2 of
concurrent cisplatin given on days 1, 22 and 43 was signifi-
cantly superior to radiotherapy alone with respect to treat-
ment outcomes [5, 6]. In definitive radiotherapy setting, the
same cisplatin regimen was also tested in phase III random-
ized fashion [7, 8]. Guided by these trials, radiochemother-
apy with three courses 100 mg/m2 of cisplatin became the
preferred regimen for both definitive and postoperative in
many institutions. However, other centers are concerned
about this regimen, since it was reported to be very toxic
[9]. Therefore, other cisplatin-regimens have been intro-
duced to the radiochemotherapy of SCCHN. One of these
alternative regimens is weekly administration of 30–
40 mg/m2 of cisplatin. In 2008, a retrospective study
showed that weekly administration of 33–40 mg/m2 of
cisplatin was better tolerated than 80–100 mg/m2 of cis-
platin given every 3 weeks [10].
Three retrospective studies and one randomized study
of 50 eligible patients had compared higher-dose cisplatin
(100 mg/m2 on days 1, 22 and 43) to weekly adminis-
tration of 30 or 40 mg/m2 of cisplatin for non-
nasopharyngeal SCCHN [11–14]. However, these studies
produced inconsistent results with respect to treatment out-
comes. One retrospective study suggested that 100 mg/m2
of cisplatin resulted in better overall survival (OS) and simi-
lar progression-free survival (PFS) compared to weekly
cisplatin [11]. In another retrospective study of patients
receiving definitive (30 %) or adjuvant (70 %) radiochemo-
therapy, 100 mg/m2 of cisplatin resulted in significantly
better PFS and OS on univariate analyses but not on multi-
variate analyses [12]. In the other two studies, outcomes
were not significantly different with 100 mg/m2 of cisplatin
given every 3 weeks or weekly administration of cisplatin
[13, 14]. Of the latter two studies, the small prospective
trial was limited to patients with cancer of the oral cavity,
and the retrospective study was performed in patients re-
ceiving postoperative radiochemotherapy (N = 104). Taking
into account the available data from the literature, it be-
comes obvious that more studies comparing 100 mg/m2 of
cisplatin every 3 weeks to weekly administration of 30 or
40 mg/m2 are required, particularly in patients receiving
definitive radiochemotherapy for SCCHN. Therefore, the
present study included only SCCHN patients receiving de-
finitive radiochemotherapy. It aimed to contribute to the
question whether weekly cisplatin is a reasonable and less
toxic alternative to 100 mg/m2 of cisplatin given every 3
weeks.
Methods
A total of 133 patients treated with definitive radiochemo-
therapy for histologically confirmed locally advanced unre-
sectable SCCHN between 2003 and 2014 were included in
this retrospective study, which was approved by the local
ethics committee (University of Lübeck). Seventy-five pa-
tients had received weekly cisplatin doses of 30–40 mg/m2
and were compared to 58 patients treated with 100 mg/m2
of cisplatin given on days 1, 22 and 43. Patients receiving
Cisplatin weekly were mainly from Ljubljana, and those re-
ceiving100 mg/m2 of cisplatin on days 1, 22 and 43 were
mainly from Northern Germany. Chemotherapy regi-
mens were selected according to interdisciplinary treat-
ment protocols preferred at the contributing institutions at
the time the patients were treated. Both groups were not
significantly different regarding the distribution of patient
characteristics including age, gender, Eastern Coopera-
tive Oncology Group (ECOG) performance score, primary
tumor site, T-category, N-category, histologic grading and
cumulative cisplatin dose (Table 1). Cancer of the oral cav-
ity was also included in this study although response to ra-
diochemotherapy is often not satisfactory for these tumors,
since it represents a common site of SCCHN. The propor-
tion of patients with cancer of the oral cavity was similar in
both groups (11 versus 12 %, Table 1).
Definitive radiotherapy was performed with 6–10
MV photon beams from a linear accelerator as three-
dimensional conformal radiotherapy after computed
tomography-based treatment planning. Patients treated
with intensity modulated radiotherapy (IMRT) and volu-
metric modulated arc therapy (VMAT) were not included.
The planned total radiation dose administered to the pri-
mary tumor and the involved lymph nodes was 70 Gy
given in 2-Gy fractions on 5 days per week (conventional
fractionation). Total doses to lymph nodes were 50–60 Gy.
Concurrent cisplatin was given as bolus infusion of 30–
40 mg/m2 once a week or as bolus infusion of 100 mg/m2
on days 1, 22 and 43. All patients received prophylactic hy-
dration and antiemetic agents and were monitored for
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potential toxicity (clinical examination, blood samples) at
least weekly.
The radiochemotherapy regimen and eight additional
characteristics (Table 1) were evaluated with respect to
LRC, MFS and OS. The HPV-status was available only in a
few patients and, therefore, not analyzed. Radiochemother-
apy regimens were additionally compared for acute and late
adverse events (Common Terminology Criteria of Adverse
Events (CTCAE) version 4.0) [15]. The follow-up schedule
included visits every 3 months for 2 years, every 6 months
during the third year, and every 12 months thereafter. Add-
itional visits were performed when toxicity-related symp-
toms occurred or progressive disease was suspected.
LRC, MFS and OS were referenced form the last day
of radiotherapy and calculated with the Kaplan-Meier-
method [16]. The corresponding Kaplan-Meier curves
were compared using the log-rank test. Those character-
istics found to be significant (p < 0.006 after Bonferroni
correction for multiple tests representing an alpha level
of 0.05) or showed a trend (p < 0.055) on univariate ana-
lyses were subsequently analyzed in a multivariate man-
ner with the Cox proportional hazards model. In the
multivariate analyses, p-values of <0.05 were considered
significant. For comparisons of the radiochemotherapy
groups for acute and late adverse events, the Chi-square
test was used.
Results
Median follow up times were 21 months (range: 0–80
months) in the entire cohort and 38 months (range: 4–
80 months) in those patients being alive at their last fol-
low up visit.
On univariate analyses, cisplatin 100 mg/m2 (Fig. 1,
p = 0.010), female gender (p = 0.010) and favorable (oro-
pharynx or larynx) primary tumor site (p = 0.047) showed a
trend towards improved LRC (Table 2). In the multivariate
analysis of LRC, radiochemotherapy regimen (p = 0.008)
and gender (p = 0.003) were significant, whereas primary
tumor site (p = 0.16) did not achieve significance (Table 5).
In the entire cohort, MFS rates at 1 and 3 years were 86
and 71 %, respectively. On univariate analysis, improved
MFS was associated with ECOG performance score
0–1 (p < 0.001), favorable (oropharynx or larynx) primary
tumor site (p = 0.002), N-category 0–2a (p = 0.001) and
histological grade 1–2 (p = 0.003) (Table 3). The radioche-
motherapy regimen was not significantly associated with
MFS (p = 0.66). On multivariate analysis of MFS, ECOG
performance score (p < 0.001) and histological grading
(p = 0.002) achieved significance, whereas N-category
(p = 0.09) and primary tumor site (p = 0.30) were not
significant (Table 5).
In the entire cohort, median survival time was 39 months,
and the OS rates at 1 and 3 years were 76 and 51 %, re-
spectively. In the univariate analyses, better OS was signifi-
cantly associated with favorable (oropharynx or larynx)
primary tumor site (p < 0.001). Cisplatin 100 mg/m2 (Fig. 1,
p = 0.024), ECOG performance score 0–1 (p = 0.006) and
female gender showed a trend (p = 0.050) (Table 4). On
multivariate analysis of OS, radiochemotherapy regi-
men (p = 0.023), ECOG performance score (p = 0.029)
and gender (p = 0.026) achieved significance, whereas
primary tumor site (p = 0.32) did not (Table 5).
The comparison of both radiotherapy groups for acute
and late adverse events revealed that 100 mg/m2 of cis-
platin was associated with significantly higher rates of
grade ≥3 hematotoxicity (p = 0.004), grade ≥2 renal fail-
ure (p = 0.004), and pneumonia/sepsis showed a trend
(p = 0.033) (Table 6). The rates of grade ≥2 oral mucosi-
tis (p = 0.95), grade ≥2 skin toxicity (p = 0.25), grade ≥2
Table 1 Comparison of the distributions of patient characteristics in
the radiochemotherapy groups (30–40 mg/m2 of cisplatin weekly vs.







≤56 years (N = 67) 37 (49) 30 (52)
≥ 57 years (N = 66) 38 (51) 28 (48) 0.92
Gender
Female (N = 29) 15 (20) 14 (24)
Male (N = 104) 60 (80) 44 (76) 0.86
ECOG Performance score
0–1 (N = 115) 64 (85) 51 (88)
2 (N = 18) 11 (15) 7 (12) 0.92
Primary tumor site
Oropharynx (N = 69) 36 (48) 33 (57)
Hypopharynx (N = 19) 12 (16) 7 (12)
Larynx (N = 30) 19 (25) 11 (19)
Oral cavity/Floor
of mouth (N = 15)
8 (11) 7 (12) 0.88
T-category
T1-2 (N = 16) 9 (12) 7 (12)
T3-4 (N = 117) 66 (88) 51 (88) 0.99
N-category
N0-2a (N = 66) 39 (52) 27 (47)
N2b-3 (N = 67) 36 (48) 31 (53) 0.75
Histologic grading
G 1–2 (N = 85) 49 (65) 36 (62)
G3 (N = 48) 26 (35) 22 (38) 0.89
Cumulative cisplatin dose
≤200 mg/m2 (N = 85) 51 (68) 34 (59)
>200 mg/m2 (N = 48) 24 (32) 24 (41) 0.50
After Bonferroni correction for multiple tests (8 tests), p-values of <0.006 were
considered significant
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xerostomia (p = 0.44) and grade ≥2 subcutaneous fibrosis
(p = 0.20) were not significantly different in both groups.
The complete planned chemotherapy could be adminis-
tered in 63 % (47/75) of patients in the cisplatin weekly
group and in 50 % (29/58) of patients in the cisplatin
100 mg/m2 group, respectively (p = 0.34). A total radi-
ation dose of 70 Gy could be administered in 92 % (69/75)
and 95 % (55/58) of patients, respectively (p = 0.87). Death
during radio-chemotherapy occurred in 4 % (3/75) and
2 % (1/58) of patients, respectively (p = 0.48).
Discussion
Definitive radiochemotherapy is one of the most common
treatment approaches for locally advanced SCCHN. In
order to achieve the best possible outcomes, irradiation and
chemotherapy should be administered concurrently [4].
The most important agent for definitive radiochemotherapy
of SCCHN is cisplatin either given alone or as part of com-
bined chemotherapy regimens. The most commonly used
of these regimens worldwide is 100 mg/m2 of cisplatin alone
given every 3 weeks, i.e. on days 1, 22 and 43. This regimen
can be associated with high rates of severe adverse events
[9]. Therefore, alternative cisplatin regimens became rela-
tively popular for radiochemotherapy of SCCHN, such as
two courses of 20 mg/m2 cisplatin on five consecutive days
or weekly administration of 30–40 mg/m2 [10–14, 17, 18].
The latter regimen is particularly used for patients who do
not wish to stay in hospital during chemotherapy.
It is not yet clear whether weekly administration of
30–40 mg/m2 cisplatin is as effective as the “standard”
Fig. 1 Comparison of the radiochemotherapy groups (30–40 mg/m2 of cisplatin weekly vs. 100 mg/m2 of cisplatin every 3 weeks) for
locoregional control (top) and overall survival (bottom)
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regimen 100 mg/m2 of cisplatin given every 3 weeks.
The available studies performed in patients with non-
nasopharyngeal SCCHN produced inconsistent results. In a
retrospective study of 94 patients, 100 mg/m2 of cisplatin
resulted in better OS (p = 0.041) and similar PFS (p= 0.47)
[11]. However, patients in the cisplatin-weekly group were
significantly older (p = 0.001), which likely have introduced
a bias. A more recent retrospective study suggested that
100 mg/m2 cisplatin every 3 weeks resulted in better PFS
and OS than weekly administration of 40 mg/m2 cisplatin
[12]. The 5-year PFS rates were 56 and 44 %, respectively,
and the 5-year OS rates 62 and 53 %, respectively. Both dif-
ferences achieved significance in the univariate analyses but
not in the multivariate analyses. In that study, 30 % of pa-
tients received definitive radiochemotherapy and 70 %
radiochemotherapy following surgery or induction chemo-
therapy. The heterogeneity of treatment regimens may have
confounded the results. Another retrospective study com-
pared 100 mg/m2 cisplatin every 3 weeks to weekly admin-
istration of 30 mg/m2 cisplatin in a more homogeneously
treated cohort of patients, who all received radiochemother-
apy following surgery [13]. Three-year LRC rates were 71
and 74 %, respectively (p = 0.95), and 3-year OS rates 84
and 75 %, respectively (p = 0.30). In addition to these retro-
spective studies, one randomized trial was performed that
compared 100 mg/m2 cisplatin every 3 weeks to 40 mg/m2
cisplatin weekly [14]. The 1-year LRC rates were 71 and
60 %, respectively (p = 0.81), and 1-year OS rates were 79
and 72 %, respectively (p = 0.98). The sample size of 50
Table 2 Univariate analysis of locoregional control (LRC)
At 1 year (%) At 3 years (%) P
Radiochemotherapy regimen
Cisplatin weekly (N = 75) 70 58
Cisplatin 100 mg/m2 (N = 58) 85 78 0.010
Age
≤56 years (N = 67) 78 65
≥57 years (N = 66) 74 68 0.72
Gender
Female (N = 29) 92 87
Male (N = 104) 72 61 0.010
ECOG Performance score
0–1 (N = 115) 78 69
2 (N = 18) 66 49 0.14
Primary tumor site
Oropharynx (N = 69) 83 74
Hypopharynx (N = 19) 47 47
Larynx (N = 30) 79 67
Oral cavity/Floor of mouth (N= 15) 75 56 0.047
T-category
T1–2 (N = 16) 93 76
T3–4 (N = 117) 74 65 0.28
N-category
N0-2a (N = 66) 76 68
N2b-3 (N = 67) 76 65 0.93
Histologic grading
G 1–2 (N = 85) 77 69
G3 (N = 48) 75 63 0.65
Cumulative cisplatin dose
≤200 mg/m2 (N = 85) 70 62
>200 mg/m2 (N = 48) 86 74 0.09
After Bonferroni correction for multiple tests, p-values of <0.006 were
considered significant
Table 3 Univariate analysis of metastases-free survival (MFS)
At 1 year (%) At 3 years (%) P
Radiochemotherapy regimen
Cisplatin weekly (N = 75) 89 68
Cisplatin 100 mg/m2 (N = 58) 83 76 0.66
Age
≤56 years (N = 67) 85 71
≥57 years (N = 66) 88 72 0.30
Gender
Female (N = 29) 79 69
Male (N = 104) 89 72 0.59
ECOG Performance score
0–1 (N = 115) 92 79
2 (N = 18) 52 25 <0.001
Primary tumor site
Oropharynx (N = 69) 89 78
Hypopharynx (N = 19) 71 61
Larynx (N = 30) 100 77




T1–2 (N = 16) 93 85
T3–4 (N = 117) 85 69 0.93
N-category
N0-2a (N = 66) 97 81
N2b-3 (N = 67) 76 62 0.001
Histologic grading
G 1–2 (N = 85) 95 76
G3 (N = 48) 72 63 0.003
Cumulative cisplatin dose
≤200 mg/m2 (N = 85) 87 71
>200 mg/m2 (N = 48) 86 73 0.69
After Bonferroni correction for multiple tests, p-values of <0.006 were
considered significant
Bold values represent significant p-values
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eligible patients was too small to achieve an adequate statis-
tical power. Furthermore, the trial was limited to patients
with cancer of the oral cavity and may not be generalized to
other sites of SCCHN.
Thus, more studies comparing 30–40 mg/m2 weekly to
100 mg/m2 given every 3 weeks for radiochemotherapy of
SCCHN would be helpful, ideally in form of a randomized
trial with an adequate statistical power. However, such a
trial will likely be difficult to perform, since most centers
wish to keep on using their preferred radiochemotherapy
regimen. Therefore, the present retrospective study was ini-
tiated to provide additional information to answer this im-
portant question. It included only patients, who had
received definitive radiochemotherapy, to avoid a potential
selection bias caused by different types of treatment. How-
ever, when interpreting the results of this study one has to
keep in mind that this study is retrospective in nature.
Retrospective studies always bear the risk of including hid-
den selection biases.
There could have been different proportions of HPV-
positive tumors in both radiochemotherapy groups. The
HPV-status was not available in most patients and, there-
fore, not included in the analyses. In previous reports from
Slovenia and Northern Germany, 20 and 15 % respectively
of oropharynx cancers were HPV-positive [19, 20]. Further
limitations of this study included the facts that the radio-
chemotherapy groups were not compared for treating insti-
tution, that patients receiving IMRT or VMAT were not
included and that both radiochemotherapy groups were
Table 4 Univariate analysis of overall survival (OS)
At 1 year (%) At 3 years (%) P
Radiochemotherapy regimen
Cisplatin weekly (N = 75) 71 45
Cisplatin 100 mg/m2 (N = 58) 83 60 0.026
Age
≤56 years (N = 67) 77 54
≥57 years (N = 66) 74 49 0.50
Gender
Female (N = 29) 89 70
Male (N = 104) 72 47 0.050
ECOG Performance score
0–1 (N = 115) 78 56
2 (N = 18) 61 14 0.006
Primary tumor site
Oropharynx (N = 69) 78 61
Hypopharynx (N = 19) 53 21
Larynx (N = 30) 83 59




T1–2 (N = 16) 81 63
T3–4 (N = 117) 75 50 0.85
N-category
N0-2a (N = 66) 79 60
N2b-3 (N = 67) 73 42 0.14
Histologic grading
G 1–2 (N = 85) 78 52
G3 (N = 48) 73 51 0.47
Cumulative cisplatin dose
≤ 200 mg/m2 (N = 85) 69 46
> 200 mg/m2 (N = 48) 87 61 0.13
After Bonferroni correction for multiple tests, p-values of <0.006 were
considered significant
Bold values represent significant p-values
Table 5 Results of the multivariate analyses of locoregional



















(0–1 vs. 2) 5.63 2.19–14.11 <0.001
N-category
(N0-2a vs. N2b-3) 2.02 0.90–4.84 0.09
Histological grading











(female vs. male) 1.98 1.08–3.96 0.026
ECOG performance score





Bold values represent significant p-values
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compared for patient characteristics with the Chi-square
test instead of using propensity score matching.
According to the results of the present study, 100 mg/m2
cisplatin given every 3 weeks led to better LRC and OS than
weekly administration of 30–40 mg/m2 cisplatin. Summar-
izing the results of both studies with respect to treatment
outcomes, 100 mg/m2 cisplatin appears preferable to weekly
administration of 30–40 mg/m2 cisplatin for definitive ra-
diochemotherapy of SCCHN. However, one question is
whether improved outcomes are impaired by more serious
adverse events? Ho et al. reported that 100 mg/m2 cisplatin
was less tolerated than weekly administration of 40 mg/m2
cisplatin [10]. In contrast, Tsan et al. observed a higher rate
of grade ≥3 oral mucositis (75 versus 39 %, p = 0.012) and a
higher rate of grade ≥3 overall toxicity (92 versus 81 %, p =
0.02) in the 40 mg/m2 cisplatin-weekly group [14]. In the
study of Espeli et al., 100 mg/m2 cisplatin resulted in more
renal failures (p = 0.04) [11]. In the largest study so far (Fay-
ette et al.), 100 mg/m2 cisplatin was associated with signifi-
cantly more adverse events than weekly administration of
40 mg/m2 cisplatin [12]. The rates of grade 3/4 mucositis
were 34 and 12 %, respectively (p < 0.001), and the rates of
grade 3/4 dermatitis were 7 and 1 %, respectively (p =
0.014). Decrease of creatinine clearance was also more pro-
nounced in the 100 mg/m2 cisplatin group (p < 0.001). Also
in the present study, some of the acute adverse events were
significantly more frequent in the 100 mg/m2 cisplatin
group (Table 5). These findings demonstrate that patients
receiving definitive radiochemotherapy with 100 mg/m2
cisplatin on days 1, 22 and 42 require intensive monitoring
(clinical examination, bone marrow function, renal func-
tion) and timely supportive care. If they are able to with-
stand this intensive radiochemotherapy regimen, they can
benefit in terms of LRC and OS. I may be questioned why
more patients treated with 100 mg/m2 cisplatin received a
cumulative dose >200 mg/m2 than in the weekly cisplatin
group, although 100 mg/m2 cisplatin was associated with
more acute toxicity? This finding can to a certain extent be
explained by the reduced compliance of some patients. In
the cisplatin weekly group, the weekly cisplatin dose was
30 mg/m2 in 71 of 75 patients. If such a patient refused the
last administration of cisplatin, the cumulative dose was
only 180 mg/m2. Of the 71 patients receiving weekly cis-
platin doses of 30 mg/m2, nine patients (13 %) received a
cumulative dose of only 180 mg/m2 without developing a
grade 3 acute toxicity.
Conclusions
Definitive radiochemotherapy with 100 mg/m2 of cisplatin
given on days 1, 22 and 43 resulted in better LRC and OS
than weekly doses of 30–40 mg/m2. Thus, 100 mg/m2 of
cisplatin appears preferable for definitive radiochemother-
apy of locally advanced SCCHN. However, one should be
aware that the regimen including 100 mg/m2 of cisplatin
given every 3 weeks is associated with considerable acute
toxicity. Patients receiving this regimen need close monitor-
ing and timely supportive care.
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Grade ≥2 70 (93) 55 (95) 0.95
Skin reactions
Grade ≥2 48 (64) 48 (83) 0.25
Hematotoxicity
Grade ≥3 7 (9) 19 (33) 0.004
Renal failure
Grade ≥2 2 (3) 12 (21) 0.004
Pneumonia/Sepsis
Grade ≥3 1 (1) 7 (12) 0.033
Xerostomiaa
Grade ≥2 28/60 (47) 34/58 (59) 0.44
Subcutaneous fibrosisa
Grade ≥2 27/72 (38) 28/51 (55) 0.20
anot available in all patients
After Bonferroni correction for multiple tests (7 tests), p-values of <0.007 were
considered significant
Bold values represent significant p-values
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